LB PharmaceuticalsCommon Stock Overview
Valuation check: LBRX's P/E ratio is -12.45, below the Healthcare sector average of 25.72.
Get informed when a big investor buys or sells
+ Follow-12.45
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
LB PharmaceuticalsCommon Stock (LBRX) currently reports a P/E ratio of -12.45. That is below the Healthcare sector average of 25.72. Use the charts on this page to explore LB PharmaceuticalsCommon Stock's P/E ratio history and peer comparisons.
LB PharmaceuticalsCommon Stock's P/E ratio of -12.45 is lower than the Healthcare sector average of 25.72. That is roughly 148.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates LB PharmaceuticalsCommon Stock's market price to a fundamental measure such as earnings, sales, or book value. At -12.45, LBRX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -12.45, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.72. From there, open related valuation or income-statement pages for LB PharmaceuticalsCommon Stock, and consider following LBRX for alerts when major investors trade the stock.
LB PharmaceuticalsCommon Stock is classified in the Healthcare sector. On P/E ratio, it currently shows -12.45 versus a sector average near 25.72. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LBRX with unrelated industries.
